Quarterly report · Q2
9776.TEDINET S100S73T
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥9.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥20.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥10.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥291m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥493m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥296m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥589m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥386m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥508m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥226m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥569m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥258m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥226m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥319m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥16.7bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥16.5bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥16.2bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.7bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥5.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥11.0bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥10.9bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥10.5bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.1bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.7bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥810m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥674m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥171m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥409m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥292m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥238m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥348m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥223m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥67.94 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.23 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥170.53 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥77.37 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥54.09 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 64.4% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.1% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.2% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥58m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥56m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥41m |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥78m |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥377m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥798m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥492m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥306m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥7m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥10.1bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥9.8bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥306m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥448m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥10.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥9.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥308m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥489m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥46m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥44m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥30m |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥371m |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥5.2bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥5.2bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥356m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥805m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥472m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥333m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥6m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥10.3bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥9.9bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥333m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥721m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥10.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥10.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥334m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥751m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 549
| Item | Context | Value | Unit |
|---|---|---|---|
| Collection of long term loans receivable inv cf | Prior1YTDDuration | 7000 | JPY |
| Collection of long term loans receivable inv cf | CurrentYTDDuration | 21000 | JPY |
| Payments for asset retirement obligations inv cf | Prior1YTDDuration | -20000000 | JPY |
| Payments for asset retirement obligations inv cf | CurrentYTDDuration | － | JPY |
| Other net inv cf | Prior1YTDDuration | 9983000 | JPY |
| Other net inv cf | CurrentYTDDuration | 24383000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | 292136000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -170535000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -66846000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -65171000 | JPY |
| Repayments of lease obligations fin cf | Prior1YTDDuration | -50437000 | JPY |
| Repayments of lease obligations fin cf | CurrentYTDDuration | -64285000 | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | -29214000 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | － | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -76984000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -76513000 | JPY |
| Dividends paid to non controlling interests fin cf | Prior1YTDDuration | － | JPY |
| Dividends paid to non controlling interests fin cf | CurrentYTDDuration | -32000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -223483000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -237969000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 742442000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 401036000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 2980620000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 3654048000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 3723063000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 4055085000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YTDDuration | － | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYTDDuration | 6547000 | JPY |
| Directors compensations sga | Prior1YTDDuration | 62968000 | JPY |
| Directors compensations sga | CurrentYTDDuration | 59044000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration | 1142427000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration | 1169672000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 181448000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 179975000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 13642000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 14212000 | JPY |
| Provision for directors retirement benefits sga | Prior1YTDDuration | 4784000 | JPY |
| Provision for directors retirement benefits sga | CurrentYTDDuration | 3898000 | JPY |
| Depreciation sga | Prior1YTDDuration | 94084000 | JPY |
| Depreciation sga | CurrentYTDDuration | 75545000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | 4223739000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | 5224204000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | 472248000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 9920192000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 44161000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 9964353000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | 332586000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 332586000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |